Evommune, Inc.
Close on Oct 19, 2026
- Market cap
- $190.43M
- P/E (TTM)
- –
- Dividend yield
- –
About Evommune
Pharmaceutical Preparations, SIC 2834
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing a portfolio of product candidates that target key drivers of chronic inflammation, with initial clinical development programs in chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its pipeline features EVO756, an oral small molecule antagonist targeting MRGPRX2 to modulate mast cells and peripheral sensory neurons, and EVO301, an engineered IL-18 binding protein fusion molecule. The company aims to address treatment gaps for patient populations suffering from chronic inflammatory conditions.
The company conducts clinical and operational activities in the United States, including multicenter clinical trials. Evommune's principal executive offices are located in Palo Alto, California, and the company also maintains leased office facilities in New York.
Summary of the business section of Evommune's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Evommune, Inc.
- Headquarters
- Palo Alto, CA
- Address
- 1891 Page Mill Rd
- Phone
- (650) 223-7745
- Employees
- 48, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, New York, NY
Stock & identifiers
- Ticker
- EVMN
- Exchange
- NYSE
- IPO date
- Nov 6, 2025
- Shares outstanding
- 36M, Aug 4, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2044725
- CUSIP
- 30054Y107
- ISIN
- US30054Y1073
- EIN
- 85-0742575
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Luis C. Pena | President & CEO, Director | 630,458 |
| Eugene Bauer | Chief Medical Officer, Director | 270,818 |
| Kyle Carver | Chief Financial Officer | 60,335 |
| Janice Suzann Drew | Chief of Dev. Operations | 71,633 |
| Jeegar Pravinkumar Patel | Chief Scientific Officer | 46,403 |
| Gregory S. Moss | Chief Business & Legal Officer | 64,010 |
| Arthur S. Kirsch | Director | 10,000 |
| Benjamin F. McGraw Iii | Director | – |
| David E. Cohen | Director | 17,609 |
| 7 Cooperative UA LSP | Director | 10,217,946 |
| Weegen Felice Isabel Verduyn-van | Director | 5,288,313 |
| Peter Kolchinsky | Director | – |
| Capital Healthcare Fund LP RA | Director | 2,710,293 |
| RA Capital Nexus Fund III, L.P. | Director | – |
| Rajeev M. Shah | Director | – |
| Ra Capital Management, L.P. | Director | 784,345 |
| Robert Lorne Hopfner | Director | 3,372,001 |
| Pivotal bioVenture Partners Fund I, L.P. | Director | – |
| bioVenture Partners Fund I. U.G.P. Ltd Pivotal | Director | – |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Director | 294,502 |
| Derek DiRocco | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 6, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 4, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |